GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.63

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.12M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+0.84 (+0.19%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+0.94 (+0.14%)

USD 78.92B
ARGX argenx NV ADR

+6.65 (+1.03%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

-5.20 (-1.86%)

USD 30.22B
MRNA Moderna Inc

-4.22 (-9.39%)

USD 18.29B
RPRX Royalty Pharma Plc

+0.01 (+0.03%)

USD 18.12B
SMMT Summit Therapeutics PLC

-1.86 (-7.91%)

USD 17.52B
UTHR United Therapeutics Corporatio..

+1.90 (+0.51%)

USD 15.91B
INCY Incyte Corporation

+0.57 (+0.78%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.21 (+0.33%)

USD 12.74B

ETFs Containing GRI

IUKP:SW iShares UK Property UCITS.. 3.33 % 0.00 %

N/A

USD 0.59B
UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

-0.02 (-0.48%)

N/A
IUKP:LSE iShares UK Property UCITS 0.00 % 0.00 %

-2.50 (-0.48%)

USD 0.59B
UKRE:LSE iShares MSCI Target UK Re.. 0.00 % 0.00 %

-2.10 (-0.48%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.95% 13% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.95% 13% F 8% B-
Trailing 12 Months  
Capital Gain -97.01% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.01% 3% F 1% F
Trailing 5 Years  
Capital Gain -100.00% N/A F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -100.00% N/A F N/A F
Average Annual (5 Year Horizon)  
Capital Gain -36.86% 8% B- 4% F
Dividend Return -36.86% 8% B- 4% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.08% 66% D+ 41% F
Risk Adjusted Return -78.30% 12% F 7% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector